HC Wainwright Issues Pessimistic Estimate for TLSI Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Stock analysts at HC Wainwright decreased their FY2026 EPS estimates for TriSalus Life Sciences in a research report issued to clients and investors on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.62) per share for the year, down from their previous forecast of ($0.53). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for TriSalus Life Sciences’ Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.16) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.10) EPS and FY2027 earnings at ($0.55) EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $12.88 million for the quarter, compared to analyst estimates of $14.02 million.

Other analysts also recently issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Wednesday, November 4th. Guggenheim set a $12.00 price target on TriSalus Life Sciences in a report on Wednesday, September 23rd. Canaccord Genuity Group reduced their price objective on TriSalus Life Sciences from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday. Stifel Nicolaus set a $12.00 price objective on TriSalus Life Sciences in a report on Wednesday, September 23rd. Finally, Zacks Research raised TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.20.

TriSalus Life Sciences Stock Up 9.6%

Shares of NASDAQ TLSI opened at $2.52 on Friday. The company has a quick ratio of 4.97, a current ratio of 4.22 and a debt-to-equity ratio of 47.60. TriSalus Life Sciences has a 1-year low of $2.20 and a 1-year high of $7.95. The company has a fifty day moving average price of $4.10 and a 200 day moving average price of $4.31.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. First Light Asset Management LLC bought a new stake in shares of TriSalus Life Sciences during the 1st quarter worth approximately $20,267,000. BlackRock Inc. acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $12,099,000. Nantahala Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $4,550,000. White Pine Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $2,143,000. Finally, State Street Corp grew its stake in shares of TriSalus Life Sciences by 86.3% in the second quarter. State Street Corp now owns 610,963 shares of the company’s stock valued at $2,780,000 after buying an additional 282,943 shares in the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.